Boston Scientific Corporation (NYSE: BSX) is 4.41% higher on its value in year-to-date trading and has touched a low of $34.98 and a high of $48.87 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BSX stock was last observed hovering at around $47.60 in the last trading session, with the day’s gains setting it 0.71% off its average median price target of $53.00 for the next 12 months. It is also 18.12% off the consensus price target high of $59.00 offered by 29 analysts, but current levels are -7.36% lower than the price target low of $45.00 for the same period.
Currently trading at $48.31, the stock is 2.73% and 3.47% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 10.2 million and changing 1.49% at the moment leaves the stock 13.79% off its SMA200. BSX registered 15.85% gain for a year compared to 6-month gain of 11.16%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
The stock witnessed a 2.29% loss in the last 1 month and extending the period to 3 months gives it a 4.50%, and is 2.74% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.09% over the week and 1.62% over the month.
Boston Scientific Corporation (BSX) has around 45000 employees, a market worth around $70.18B and $12.68B in sales. Current P/E ratio is 108.32 and Fwd P/E is 22.47. Profit margin for the company is 5.10%. Distance from 52-week low is 38.11% and -1.14% from its 52-week high. The company has generated returns on investments over the last 12 months (3.80%).
Boston Scientific Corporation (BSX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Boston Scientific Corporation (BSX) is a “Buy”. 29 analysts offering their recommendations for the stock have an average rating of 1.80, where 4 rate it as a Hold and 4 think it is a “Overweight”. 21 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Boston Scientific Corporation is expected to release its quarterly report on 04/26/2023.The EPS is expected to shrink by -35.10% this year.
Boston Scientific Corporation (BSX) Top Institutional Holders
The shares outstanding are 1.43B, and float is at 1.43B with Short Float at 0.89%.
Boston Scientific Corporation (BSX) Insider Activity
A total of 119 insider transactions have happened at Boston Scientific Corporation (BSX) in the last six months, with sales accounting for 65 and purchases happening 54 times. The most recent transaction is an insider sale by Brennan Daniel J.,the company’sEVP and CFO. SEC filings show that Brennan Daniel J. sold 30,000 shares of the company’s common stock on Mar 02 at a price of $46.66 per share for a total of $1.4 million. Following the sale, the insider now owns 0.23 million shares.
Boston Scientific Corporation disclosed in a document filed with the SEC on Mar 01 that Brennan Daniel J. (EVP and CFO) sold a total of 75,610 shares of the company’s common stock. The trade occurred on Mar 01 and was made at $46.64 per share for $3.53 million. Following the transaction, the insider now directly holds 0.26 million shares of the BSX stock.
Still, SEC filings show that on Mar 01, Monson Jonathan (SVP, Global Controller and CAO) disposed off 5,000 shares at an average price of $46.66 for $0.23 million. The insider now directly holds 34,868 shares of Boston Scientific Corporation (BSX).
Boston Scientific Corporation (BSX): Who are the competitors?
The company’s main competitors (and peers) include Abbott Laboratories (ABT) that is trading -13.57% down over the past 12 months and Medtronic plc (MDT) that is -25.00% lower over the same period. Stryker Corporation (SYK) is 11.27% up on the 1-year trading charts.